LeMaitre Vascular, Inc. $LMAT Shares Acquired by AlphaQuest LLC

Key Points

• AlphaQuest LLC significantly increased its stake in LeMaitre Vascular, raising its holdings by 9,787.2% during the 1st quarter to 8,503 shares valued at $713,000.
• Insider transactions revealed substantial sales, with directors selling a total of 120,815 shares worth over $11 million in the last three months, leading to notable decreases in their ownership percentages.
• LeMaitre Vascular's recent earnings report showed an EPS of $0.60, surpassing expectations, along with a declared quarterly dividend of $0.20 per share, reflecting a dividend yield of 0.8%.

AlphaQuest LLC boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 9,787.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,503 shares of the medical instruments supplier's stock after acquiring an additional 8,417 shares during the period. AlphaQuest LLC's holdings in LeMaitre Vascular were worth $713,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. EntryPoint Capital LLC raised its holdings in shares of LeMaitre Vascular by 22.5% in the first quarter. EntryPoint Capital LLC now owns 5,438 shares of the medical instruments supplier's stock worth $456,000 after buying an additional 998 shares during the last quarter. Credit Agricole S A raised its holdings in shares of LeMaitre Vascular by 80.1% in the first quarter. Credit Agricole S A now owns 18,877 shares of the medical instruments supplier's stock worth $1,584,000 after buying an additional 8,393 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of LeMaitre Vascular in the first quarter worth $50,000. Aptus Capital Advisors LLC purchased a new position in shares of LeMaitre Vascular in the first quarter worth $4,483,000. Finally, Northern Trust Corp raised its holdings in shares of LeMaitre Vascular by 5.4% in the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier's stock worth $28,993,000 after buying an additional 17,748 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on LMAT. Cantor Fitzgerald raised their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a report on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, LeMaitre Vascular has a consensus rating of "Hold" and an average price target of $97.60.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock traded down $0.41 during trading on Thursday, hitting $95.27. 130,646 shares of the company's stock were exchanged, compared to its average volume of 191,649. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The business has a 50-day simple moving average of $86.86 and a 200-day simple moving average of $86.43. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of 46.25, a PEG ratio of 2.45 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm's revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the business earned $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio (DPR) is currently 38.83%.

Insider Activity

In related news, Director David B. Roberts sold 10,815 shares of the firm's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the sale, the director owned 17,976 shares in the company, valued at approximately $1,660,802.64. This trade represents a 37.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bridget A. Ross sold 2,500 shares of the firm's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $94.00, for a total transaction of $235,000.00. Following the sale, the director owned 2,916 shares in the company, valued at approximately $274,104. This represents a 46.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,815 shares of company stock worth $11,280,206 in the last ninety days. Corporate insiders own 9.50% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.